Market Spotlight: Gastrointestinal Stromal Tumor (GIST)
|出版日期||內容資訊||英文 42 Pages
|市場焦點:胃腸道基質腫瘤(GIST) Market Spotlight: Gastrointestinal Stromal Tumor (GIST)|
|出版日期: 2020年07月21日||內容資訊: 英文 42 Pages||
本報告提供胃腸道基質腫瘤 (GIST) 市場上主要的已上市藥、開發平台藥物，近幾年的動向和分析師的見解，臨床試驗，不久將來的動向、規定趨勢，成功的可能性，專利資訊，及10年的發病率預測，授權、資產取得交易，以及各類醫藥品的收益預測等相關分析。
This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, licensing and asset acquisition deals, and drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2019, there were 100,200 incident cases of gastrointestinal stromal tumor (GIST) worldwide, and expects that number to increase to 109,000 incident cases by 2028.
The approved drugs in the GIST space target BCR-ABL fusion protein, KIT/c-KIT, platelet-derived growth factor receptor, plateletderived growth factor alpha, Raf kinase, VEGF receptor, and FMS-like tyrosine kinase 3. These therapies are administered via the oral route.
The largest proportion of industry-sponsored drugs in active clinical development for GIST are in Phase II. Therapies in development for GIST focus on a wide variety of targets. The majority of pipeline drugs in development are administered orally, with the remainder being tested in intravenous formulations.
An expected CHMP opinion for Ayvakit is the only high-impact upcoming event in the GIST space. The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 43%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for GIST have been in the early and midphases of development, with 83% of trials in Phase I-II, and only 17% in Phase III-IV.
The US has a substantial lead in the number of GIST clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
Clinical trial activity in the GIST space is dominated by completed trials. Novartis has the highest number of completed clinical trials for GIST, with 65 trials.
Novartis leads industry sponsors with by far the highest overall number of clinical trials for GIST.